Overall, this study identified that AhR activation drives abnormal erythrocyte and PLT differentiation in individuals with cancer, and targeting the Kyn–AhR pathway could be explored to treat anemia and thrombocytosis in individuals with cancer. The gene discussed is AHR; the disease is anemia (phenotype).